Dashboard
Manage Tickers

AMRXAmneal Pharmaceuticals, Inc.

NYSE amneal.com


$ 5.88 $ -0.03 (-0.51 %)    

Friday, 26-Apr-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.01 $ 3.03 (0.71 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.48 (0.55 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 5.87
$ 5.85
$ 0.00 x 0
$ 0.00 x 0
$ 5.85 - $ 5.97
$ 1.72 - $ 6.46
959,053
na
1.03B
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-03-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-06-2022 03-31-2022 10-Q
9 03-01-2022 12-31-2021 10-K
10 11-08-2021 09-30-2021 10-Q
11 08-09-2021 06-30-2021 10-Q
12 05-07-2021 03-31-2021 10-Q
13 03-01-2021 12-31-2020 10-K
14 11-06-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-02-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-05-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-01-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-15-2018 03-31-2018 10-Q
25 03-09-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

amneal-announces-fda-approval-of-over-the-counter-naloxone-hydrochloride-nasal-spray-for-emergency-treatment-of-opioid-overdose
Amneal Announces FDA Approval Of Over-The-...
04/24/2024 12:12:36

amneal-launches-pemrydi-rtu-the-first-ready-to-use-version-of-important-oncology-injectable-medicine
Amneal Launches PEMRYDI RTU, The First Rea...
04/16/2024 12:16:46

Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mes...

Core News & Articles
Bausch Health Announces Patent Lawsuit Aga...
04/05/2024 22:27:59

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announc...

amneal-receives-fda-approval-for-ciprofloxacin-and-dexamethasone-otic-suspension
Amneal Receives FDA Approval For Ciproflox...
03/25/2024 20:13:18

- Product references branded Ciprodex - Represents another complex, high value new product

Core News & Articles
FTC Files Amicus Brief in Asthma Inhaler P...
03/22/2024 17:56:54

-Wall Street Journal

piper-sandler-maintains-overweight-on-amneal-pharmaceuticals-raises-price-target-to-8
Piper Sandler Maintains Overweight on Amne...
03/21/2024 18:06:47

Piper Sandler analyst David Amsellem maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price t...

goldman-sachs-maintains-buy-on-amneal-pharmaceuticals-raises-price-target-to-625
Goldman Sachs Maintains Buy on Amneal Phar...
03/04/2024 14:20:36

Goldman Sachs analyst Nathan Rich maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from...

why-is-generic-drug-focused-amneal-pharmaceuticals-stock-trading-lower-friday
Why Is Generic Drug-Focused Amneal Pharmac...
03/01/2024 15:57:45

Amneal Pharmaceuticals reveals Q4 2023 results with $616.98 million revenue, up 1% YoY. Despite an 8% drop in adjusted EBITDA, ...

amneal-pharmaceuticals-shares-are-trading-higher-after-the-company-reported-mixed-q4-earnings-and-issued-2024-guidance
Amneal Pharmaceuticals shares are trading ...
03/01/2024 11:58:27

earnings-scheduled-for-march-1-2024
Earnings Scheduled For March 1, 2024
03/01/2024 11:56:41

Companies Reporting Before The Bell • McEwen Mining (NYSE:MUX) is estimated to report quarterly loss at $0.28 per share on rev...

amneal-pharmaceuticals-q4-earnings-insights
Amneal Pharmaceuticals: Q4 Earnings Insights
03/01/2024 11:40:06

amneal-expects-fiscal-year-2024-adjusted-ebitda-of-580m-620m-with-operating-cash-flow-of-260m-300m-and-capital-expenditures-of-60m-70m-compared-to-558m-346m-and-43m-in-2023-respectively
Amneal Expects Fiscal Year 2024 Adjusted E...
03/01/2024 11:09:47

amneal-forecasts-fiscal-year-2024-revenues-of-255b-265b-versus-consensus-of-258b-and-adjusted-eps-of-053-063-versus-consensus-of-059
Amneal Forecasts Fiscal Year 2024 Revenues...
03/01/2024 11:06:25

amneal-pharmaceuticals-q4-adjusted-eps-014-beats-009-estimate-sales-61698m-miss-63423m-estimate
Amneal Pharmaceuticals Q4 Adjusted EPS $0....
03/01/2024 11:02:05

Amneal Pharmaceuticals (NYSE:AMRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of ...

earnings-outlook-for-amneal-pharmaceuticals
Earnings Outlook For Amneal Pharmaceuticals
02/29/2024 14:00:33

amneal-enters-into-exclusive-european-licensing-agreement-with-zambon-biotech-for-ipx203
Amneal Enters Into Exclusive European Lice...
02/27/2024 13:06:54

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced that it has entered into...

amneal-reports-complete-response-resubmission-to-fda-for-ipx203-new-drug-application
Amneal Reports Complete Response Resubmiss...
02/08/2024 21:13:40

The original NDA for IPX203 resulted in a Complete Response Letter (CRL) from FDA. The resubmission package included data from ...

barclays-maintains-overweight-on-amneal-pharmaceuticals-raises-price-target-to-8
Barclays Maintains Overweight on Amneal Ph...
01/29/2024 12:00:51

Barclays analyst Balaji Prasad maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target ...

Core News & Articles
Knight Therapeutics Enters Exclusive Licen...
01/25/2024 12:31:41

amneal-launches-complex-generic-fluorometholone-ophthalmic-suspension-product-has-180-day-competitive-generic-therapy-exclusivity
Amneal Launches Complex Generic Fluorometh...
01/10/2024 13:17:15

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION